ES2337005R - Compuestos de pirazolina azepan o azocansustituidos, su preparacion y su uso como medicamentos. - Google Patents

Compuestos de pirazolina azepan o azocansustituidos, su preparacion y su uso como medicamentos. Download PDF

Info

Publication number
ES2337005R
ES2337005R ES200850016A ES200850016A ES2337005R ES 2337005 R ES2337005 R ES 2337005R ES 200850016 A ES200850016 A ES 200850016A ES 200850016 A ES200850016 A ES 200850016A ES 2337005 R ES2337005 R ES 2337005R
Authority
ES
Spain
Prior art keywords
preparation
azepan
compounds
pirazolina
azocansustituidos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200850016A
Other languages
English (en)
Other versions
ES2337005A2 (es
ES2337005B1 (es
Inventor
Antonio Torrens Jover
Susana Yenes Minguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05384018A external-priority patent/EP1743888A1/en
Priority claimed from EP06008612A external-priority patent/EP1849776A1/en
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2337005A2 publication Critical patent/ES2337005A2/es
Publication of ES2337005R publication Critical patent/ES2337005R/es
Application granted granted Critical
Publication of ES2337005B1 publication Critical patent/ES2337005B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Abstract

Compuestos de pirazolina azepan o azocansustituidos, su preparación y su uso como medicamentos.<br /><br />La presente invención se refiere a compuestos de pirazolina azepan o azocansustituidos, procedimientos para su preparación, medicamentos que comprenden estos compuestos así como su uso para la preparación de un medicamento para el tratamiento de seres humanos y animales.
ES200850016A 2005-07-15 2006-07-16 Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos. Expired - Fee Related ES2337005B1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP05384018 2005-07-15
EP05384018A EP1743888A1 (en) 2005-07-15 2005-07-15 Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
US70543305P 2005-08-05 2005-08-05
US60/705,433 2005-08-05
EP06008612A EP1849776A1 (en) 2006-04-26 2006-04-26 Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP06008612 2006-04-26

Publications (3)

Publication Number Publication Date
ES2337005A2 ES2337005A2 (es) 2010-04-19
ES2337005R true ES2337005R (es) 2010-04-23
ES2337005B1 ES2337005B1 (es) 2011-01-10

Family

ID=37326377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200850016A Expired - Fee Related ES2337005B1 (es) 2005-07-15 2006-07-16 Compuestos de pirazolina azepan o azocansustituidos, su preparacion ysu uso como medicamentos.

Country Status (2)

Country Link
ES (1) ES2337005B1 (es)
WO (1) WO2007131538A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894399A1 (en) 2012-12-06 2014-06-12 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US7517900B2 (en) * 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
EP1713475B1 (en) * 2004-01-30 2008-07-30 Solvay Pharmaceuticals B.V. 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LANGE, J. H.M. y col. Biososteric replacement of the pyrazole moiety of Rimonabant: synthesis, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry. 2005, Vol. 48, páginas 1823-1838, ISSN 0022-2623. Todo el documento. *

Also Published As

Publication number Publication date
WO2007131538A1 (en) 2007-11-22
ES2337005A2 (es) 2010-04-19
ES2337005B1 (es) 2011-01-10

Similar Documents

Publication Publication Date Title
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
GT200900027A (es) Compuestos organicos
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
CR9514A (es) Antagonistas de npy, preparacion y usos
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
EC2A Search report published

Ref document number: 20100419

FG2A Definitive protection

Ref document number: 2337005

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20101227

FD2A Announcement of lapse in spain

Effective date: 20190610